{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:04:16Z","timestamp":1791241456895,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T00:00:00Z","timestamp":1572652800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T00:00:00Z","timestamp":1572652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10388-019-00702-y","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T12:02:54Z","timestamp":1572696174000},"page":"87-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis"],"prefix":"10.1007","volume":"17","author":[{"given":"Nana","family":"Takenouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Hoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Koeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Momma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kawami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Kaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5558-6104","authenticated-orcid":false,"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,2]]},"reference":[{"key":"702_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1046\/j.1440-1746.2000.02131.x","volume":"15","author":"K Haruma","year":"2000","unstructured":"Haruma K, Kamada T, Kawaguchi H, et al. Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol. 2000;15:277\u201383.","journal-title":"J Gastroenterol Hepatol"},{"key":"702_CR2","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.cgh.2007.08.011","volume":"5","author":"J Lee","year":"2007","unstructured":"Lee J, Anggiansah A, Anggiansah R, et al. Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol. 2007;5:1392\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"702_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000367650","volume":"91","author":"N Kawami","year":"2015","unstructured":"Kawami N, Iwakiri K, Sano H, et al. Effects of aging and acid reflux on esophageal motility. Digestion. 2015;91:181\u20136.","journal-title":"Digestion"},{"key":"702_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","volume":"51","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751\u201367.","journal-title":"J Gastroenterol"},{"key":"702_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00535-010-0276-7","volume":"45","author":"K Fujimoto","year":"2010","unstructured":"Fujimoto K, Hongo M. Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan. J Gastroenterol. 2010;45:1193\u2013200.","journal-title":"J Gastroenterol"},{"key":"702_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00535-011-0446-2","volume":"46","author":"T Furuta","year":"2011","unstructured":"Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273\u201383.","journal-title":"J Gastroenterol"},{"key":"702_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000342393","volume":"86","author":"A Watanabe","year":"2012","unstructured":"Watanabe A, Iwakiri R, Yamaguchi D, et al. Risk factors for resistance to proton pump inhibitor maintenance therapy for reflux esophagitis in Japanese women over 60 years. Digestion. 2012;86:323\u20138.","journal-title":"Digestion"},{"key":"702_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3164\/jcbn.14-144","volume":"57","author":"H Mizuno","year":"2015","unstructured":"Mizuno H, Matsuhashi N, Sakaguchi M, et al. Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in Japan. J Clin Biochem Nutr. 2015;57:233\u20138.","journal-title":"J Clin Biochem Nutr"},{"key":"702_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636\u201348.","journal-title":"Aliment Pharmacol Ther"},{"key":"702_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of\u00a0vonoprazan\u00a020\u00a0mg compared with esomeprazole 20\u00a0mg or rabeprazole 10\u00a0mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"702_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of\u00a0vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 9","key":"702_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2036.2004.02240.x","volume":"20","author":"J Pisegna","year":"2004","unstructured":"Pisegna J, Holtmann G, Howden CW, et al. Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20(Suppl 9):47\u201356.","journal-title":"Aliment Pharmacol Ther"},{"key":"702_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000210097","volume":"27","author":"K Belhocine","year":"2009","unstructured":"Belhocine K, Galmiche JP. Epidemiology of the complications of gastroesophageal reflux disease. Dig Dis. 2009;27:7\u201313.","journal-title":"Dig Dis"},{"key":"702_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3748\/wjg.v23.i2.318","volume":"23","author":"M Sakaguchi","year":"2017","unstructured":"Sakaguchi M, Manabe N, Ueki N, et al. Factors associated with complicated erosive esophagitis: A Japanese multicenter, prospective, cross-sectional study. World J Gastroenterol. 2017;23:318\u201327.","journal-title":"World J Gastroenterol"},{"key":"702_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000455834","volume":"95","author":"N Kawami","year":"2017","unstructured":"Kawami N, Takenouchi N, Umezawa M, et al. Pathogenesis of double-dose proton pump inhibitor-resistant non-erosive reflux disease, and mechanism of reflux symptoms and gastric acid secretion-suppressive effect in the presence or absence of helicobacter pylori infection. Digestion. 2017;95:140\u20135.","journal-title":"Digestion"},{"key":"702_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s005350170107","volume":"36","author":"T Sugiura","year":"2001","unstructured":"Sugiura T, Iwakiri K, Kotoyori M, et al. Relationship between severity of reflux esophagitis according to the Los Angeles classification and esophageal motility. J Gastroenterol. 2001;36:226\u201330.","journal-title":"J Gastroenterol"},{"key":"702_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10388-017-0575-7","volume":"14","author":"K Iwakiri","year":"2017","unstructured":"Iwakiri K, Hoshino S, Kawami N. Mechanisms underlying excessive esophageal acid exposure in patients with gastroesophageal reflux disease. Esophagus. 2017;14:221\u20138.","journal-title":"Esophagus"},{"key":"702_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1272\/jnms.84.209","volume":"84","author":"K Iwakiri","year":"2017","unstructured":"Iwakiri K. Treatment strategy for standard dose proton pump inhibitor-resistant reflux esophagitis. J Nippon Med Sch. 2017;84:209\u201314.","journal-title":"J Nippon Med Sch."},{"key":"702_CR19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, SakuraiY Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636\u201348.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"702_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000200917","volume":"51","author":"NJ Bell","year":"1992","unstructured":"Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl 1):59\u201367.","journal-title":"Digestion"},{"key":"702_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S Hoshino","year":"2017","unstructured":"Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95:156\u201361.","journal-title":"Digestion"},{"key":"702_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10388-019-00676-x","volume":"16","author":"T Tanabe","year":"2019","unstructured":"Tanabe T, Hoshino S, Kawami N, et al. Efficacy of long term maintenance therapy with 10-mg vonoprazan for proton-pump inhibitor-resistant reflux esophagitis. Esophagus. 2019;16:377\u201381.","journal-title":"Esophagus"},{"key":"702_CR23","first-page":"1","volume":"14","author":"H Yamasaki","year":"2016","unstructured":"Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2016;14:1\u20138.","journal-title":"Xenobiotica"},{"key":"702_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1067\/mcp.2002.127637","volume":"72","author":"T Furuta","year":"2002","unstructured":"Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72:453\u201360.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-019-00702-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10388-019-00702-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-019-00702-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:39:44Z","timestamp":1604191184000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10388-019-00702-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1007\/s10388-019-00702-y","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,2]]},"assertion":[{"value":"25 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures followed were in accordance with the approval of the Ethics Committee of Nippon Medical School Hospital and the guidelines set forth in the Declaration of Helsinki revised in 2000. Informed consent was obtained from all subjects included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"Katsuhiko Iwakiri has received lecture fees from Takeda Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd.. The remaining authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}